Among 24 analysts covering USG Corporation (NYSE:USG), 7 have Buy rating, 3 Sell and 14 Hold. Therefore 29% are positive. USG Corporation had 83 analyst reports since July 29, 2015 according to SRatingsIntel. The company was downgraded on Saturday, August 29 by Zacks. The rating was maintained by Stifel Nicolaus with “Hold” on Thursday, August 31. Wedbush maintained USG Corporation (NYSE:USG) rating on Thursday, October 27. Wedbush has “Neutral” rating and $30 target. The rating was downgraded by Jefferies to “Hold” on Friday, October 23. SunTrust downgraded USG Corporation (NYSE:USG) on Monday, October 2 to “Hold” rating. The firm has “Buy” rating given on Friday, January 5 by Barclays Capital. Vertical Research upgraded USG Corporation (NYSE:USG) on Monday, September 19 to “Buy” rating. Robert W. Baird maintained the stock with “Hold” rating in Monday, August 28 report. Macquarie Research downgraded USG Corporation (NYSE:USG) on Wednesday, March 29 to “Neutral” rating. Citigroup maintained it with “Neutral” rating and $34 target in Monday, October 9 report. See USG Corporation (NYSE:USG) latest ratings:
16/04/2018 Broker: SunTrust Rating: Hold New Target: $44.0000 Maintain
16/04/2018 Broker: Buckingham Research Old Rating: Neutral New Rating: Neutral Old Target: $34 New Target: $42 Maintain
10/04/2018 Broker: Jefferies Rating: Hold New Target: $36.0000 Maintain
27/03/2018 Broker: Nomura Old Rating: Neutral New Rating: Neutral Old Target: $39 New Target: $44 Maintain
13/03/2018 Broker: Raymond James Rating: Market Perform Initiates Coverage On
08/03/2018 Broker: Robert W. Baird Rating: Buy New Target: $42.0 Maintain
06/02/2018 Broker: Stephens Rating: Hold New Target: $38.0 Maintain
02/02/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $43 New Target: $41 Maintain
01/02/2018 Broker: Jefferies Rating: Hold New Target: $36.0 Maintain
02/02/2018 Broker: Nomura Old Rating: Neutral New Rating: Neutral Old Target: $40 New Target: $39 Maintain
The stock of uniQure N.V. (NASDAQ:QURE) is a huge mover today! The stock increased 4.09% or $1.22 during the last trading session, reaching $31.02. About 104,241 shares traded. uniQure N.V. (NASDAQ:QURE) has risen 293.97% since April 18, 2017 and is uptrending. It has outperformed by 282.42% the S&P500.The move comes after 9 months positive chart setup for the $954.98M company. It was reported on Apr, 18 by Barchart.com. We have $33.19 PT which if reached, will make NASDAQ:QURE worth $66.85 million more.
USG Corporation, through its subsidiaries, makes and sells building materials worldwide. The company has market cap of $5.80 billion. The companyÂ’s Gypsum segment makes and markets gypsum and related products to construct walls, ceilings, roofs, and floors of residential, commercial, and institutional buildings, as well as for various industrial applications. It has a 69.15 P/E ratio. This segment offers gypsum panels, as well as joint compounds, corner beads, joint tapes, and plasters for wallboard joints finishing under the Sheetrock brand; cement board under the Durock brand; backerboard that includes abuse-resistant interior wall panels, tile backer boards, and flooring underlayments under the Fiberock brand; poured gypsum flooring systems under the Levelrock brand; roof boards under the Securock brand; and air-water barrier system and industrial gypsum under the ExoAir 430 brand.
The stock increased 0.34% or $0.14 during the last trading session, reaching $41.42. About 188,570 shares traded. USG Corporation (NYSE:USG) has risen 19.90% since April 18, 2017 and is uptrending. It has outperformed by 8.35% the S&P500.
Investors sentiment decreased to 0.88 in 2017 Q4. Its down 0.18, from 1.06 in 2017Q3. It is negative, as 19 investors sold USG Corporation shares while 81 reduced holdings. 38 funds opened positions while 50 raised stakes. 113.11 million shares or 5.42% less from 119.59 million shares in 2017Q3 were reported. Tcw reported 0.01% stake. Wells Fargo And Mn owns 3.08M shares. Moreover, Point72 Asia (Hong Kong) Limited has 0% invested in USG Corporation (NYSE:USG) for 94 shares. 30,100 were accumulated by Conning Inc. State Board Of Administration Of Florida Retirement System has 0.01% invested in USG Corporation (NYSE:USG) for 122,888 shares. New York-based Buckingham Cap Mgmt has invested 0.4% in USG Corporation (NYSE:USG). Raymond James Fincl Services Advisors Inc reported 65,989 shares. Punch Associate Investment Mngmt Incorporated holds 0.33% of its portfolio in USG Corporation (NYSE:USG) for 98,171 shares. Oppenheimer And invested in 0.05% or 50,855 shares. Northwestern Mutual Wealth has 0% invested in USG Corporation (NYSE:USG). Federated Invsts Pa has 0.01% invested in USG Corporation (NYSE:USG) for 97,933 shares. Winslow Evans Crocker owns 30 shares for 0% of their portfolio. Adage Cap Partners Grp Inc Limited Liability Com invested in 0.13% or 1.52 million shares. Goldman Sachs Grp Inc holds 0% or 307,652 shares in its portfolio. Ameriprise Fincl stated it has 67,868 shares or 0% of all its holdings.
Among 13 analysts covering uniQure N.V. (NASDAQ:QURE), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. uniQure N.V. had 30 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Oppenheimer given on Wednesday, June 28. On Wednesday, July 12 the stock rating was maintained by Cowen & Co with “Buy”. The company was maintained on Thursday, October 1 by Chardan Capital Markets. Zacks downgraded the stock to “Buy” rating in Tuesday, September 1 report. Leerink Swann maintained uniQure N.V. (NASDAQ:QURE) on Tuesday, September 22 with “Outperform” rating. The company was maintained on Friday, August 28 by Piper Jaffray. The company was reinitiated on Monday, November 30 by TH Capital. Chardan Capital Markets maintained uniQure N.V. (NASDAQ:QURE) on Tuesday, July 18 with “Buy” rating. The stock has “Buy” rating by Roth Capital on Monday, November 30. On Tuesday, December 1 the stock rating was maintained by WallachBeth Capital with “Buy”.
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $954.98 million. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.
Analysts await uniQure N.V. (NASDAQ:QURE) to report earnings on May, 8. They expect $-0.74 EPS, up 7.50% or $0.06 from last year’s $-0.8 per share. After $-0.91 actual EPS reported by uniQure N.V. for the previous quarter, Wall Street now forecasts -18.68% EPS growth.